Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves Financial Milestone via Largest Single-Hospital STREAMWAY(R) System Sale

Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that its Skyline Medical Division completed the sale of 10 STREAMWAY(R) Systems to a major New York hospital (http://ibn.fm/dXHwp). An article discussing the company reads, “For Predictive Oncology, this announcement represents a significant financial milestone. As POAI’s largest single-hospital transaction ever, the sale indicates the credibility and trust the STREAMWAY System is building within the industry. In addition, the sale is another positive indication that Skyline Medical, a POAI subsidiary, provides tremendous qualitative, long-term potential as it continues to focus on and develop innovative and revolutionary technology and alternatives. Through its STREAMWAY System, Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.”

To view the full article, visit http://ibn.fm/hnE61

About Predictive Oncology Inc.

Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, with more than 38,000 specific to ovarian cancer. The company’s data is highly differentiated, having both drug-response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

This entry was posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI. Bookmark the permalink.

Comments are closed.